{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:45:37Z","timestamp":1778496337585,"version":"3.51.4"},"reference-count":34,"publisher":"Informa UK Limited","issue":"16","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,6,30]]},"DOI":"10.2217\/fon-2018-0608","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T13:41:19Z","timestamp":1559137279000},"page":"1939-1945","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Ocular And Orbital Side Effects of Alk Inhibitors: A Review Article"],"prefix":"10.1080","volume":"15","author":[{"given":"Elias","family":"Chelala","sequence":"first","affiliation":[{"name":"Saint Joseph University, Faculty of Medicine, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Hoyek","sequence":"additional","affiliation":[{"name":"Saint Joseph University, Faculty of Medicine, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Arej","sequence":"additional","affiliation":[{"name":"Saint Joseph University, Faculty of Medicine, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[{"name":"Saint Joseph University, Faculty of Medicine, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[{"name":"Saint Joseph University, Faculty of Medicine, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josette","family":"Baakliny","sequence":"additional","affiliation":[{"name":"Optometry Department, Laservision Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Antoun","sequence":"additional","affiliation":[{"name":"Saint Joseph University, Faculty of Medicine, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq207"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01520-2016"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0514-z"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0622-4"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-262"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0810-4"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30123-X"},{"key":"e_1_3_2_10_1","unstructured":"US FDA . Approved Drugs \u2013 FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC (2017). www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm560873.htm"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_79_17"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70362-6"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30565-2"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_3_2_15_1","unstructured":"US FDA . Approved Drugs \u2013 alectinib approved for (ALK) positive metastatic non-small cell lung cancer (NSCLC) (2017). www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm584082.htm"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.5904"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000525"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006448"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"e_1_3_2_20_1","first-page":"163","article-title":"Zykadia (ceritinib) approved for patients with crizotinib-resistant ALK-positive non-small-cell lung cancer","volume":"8","author":"Raedler LA","year":"2015","unstructured":"Raedler LA . Zykadia (ceritinib) approved for patients with crizotinib-resistant ALK-positive non-small-cell lung cancer. Am. Health Drug Benefits8(Spec. Feature), 163\u2013166 (2015).","journal-title":"Am. Health Drug Benefits"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.1643"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30680-0"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70344-3"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1985"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.7596"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135521"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu213"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6989(84)90016-6"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1007040"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.12.021"},{"issue":"4","key":"e_1_3_2_31_1","first-page":"238","article-title":"MET inhibitors in combination with other therapies in non-small cell lung cancer","volume":"1","author":"Padda S","year":"2012","unstructured":"Padda S , NealJW, WakeleeHA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl. Lung Cancer Res.1(4), 238\u2013253 (2012).","journal-title":"Transl. Lung Cancer Res."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1926.sp002273"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1420785112"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0274"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5851"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:50Z","timestamp":1719125090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":34,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,6,30]]}},"alternative-id":["10.2217\/fon-2018-0608"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0608","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}